<DOC>
	<DOCNO>NCT01147406</DOCNO>
	<brief_summary>The purpose study evaluate safety tolerability N6022 healthy subject .</brief_summary>
	<brief_title>Safety Tolerability Study N6022 Healthy Subjects</brief_title>
	<detailed_description>This single dose escalation , first-time-in-human study three ascend cohort . Eligible subject receive single dose investigational medicinal product placebo Day 1 follow safety , PK , PD 72 hour post dose . Follow-up visit Day 4 Day 7 end-of-study safety . Participation individual subject may last 36 day time screen end-of-study follow-up visit . Each cohort enroll sentinel pair ( 1:1 randomize active : placebo ) . These subject follow 48 hour postdose safety data review remain subject cohort receive IMP . A Safety Monitoring Committee review seven-day safety data cohort proceed next ascend dose cohort , accord stop rule outline protocol .</detailed_description>
	<criteria>Inclusion : Subject healthy Exclusion : Subject current alcohol abuser and/or history illicit drug abuse within six month entry . Subject donate blood ( &gt; 500 mL ) blood product within 56 day prior Day 1</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>January 2014</verification_date>
</DOC>